NCCN Clinical Practice Guidelines in Oncology: colon cancer.

[1]  W. Willett,et al.  Physical activity and male colorectal cancer survival. , 2009, Archives of internal medicine.

[2]  A. Barsevick,et al.  The challenges of colorectal cancer survivorship. , 2009, Journal of the National Comprehensive Cancer Network : JNCCN.

[3]  Seta Shahin,et al.  A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  F. Hu,et al.  Association of dietary patterns with cancer recurrence and survival in patients with stage III colon cancer. , 2007, JAMA.

[5]  N. Wolmark,et al.  Body mass index and outcomes in patients who receive adjuvant chemotherapy for colon cancer. , 2006, Journal of the National Cancer Institute.

[6]  J. Meyerhardt,et al.  Impact of physical activity on cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  J. Hecht,et al.  Panitumumab antitumor activity in patients (pts) with metastatic colorectal cancer (mCRC) expressing low (1-9%) or negative (<1%) levels of epidermal growth factor receptor (EGFr). , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  A. Lacy,et al.  Postoperative surveillance in patients with colorectal cancer who have undergone curative resection: a prospective, multicenter, randomized, controlled trial. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  D. Samid,et al.  Phase II study of capecitabine in patients with fluorouracil-resistant metastatic colorectal carcinoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  G. Ravera,et al.  Efficacy and cost of risk-adapted follow-up in patients after colorectal cancer surgery: a prospective, randomized and controlled trial. , 2002, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[11]  P. Catalano,et al.  Surveillance for Second Primary Colorectal Cancer after Adjuvant Chemotherapy: An Analysis of Intergroup 0089 , 2002, Annals of Internal Medicine.

[12]  S. Libutti,et al.  A Prospective Study of 2-[18F] Fluoro-2-Deoxy-D-Glucose/Positron Emission Tomography Scan, 99mTc-Labeled Arcitumomab (CEA-Scan), and Blind Second-Look Laparotomy for Detecting Colon Cancer Recurrence in Patients With Increasing Carcinoembryonic Antigen Levels , 2001, Annals of Surgical Oncology.

[13]  R. Costi,et al.  Role of follow-up in management of local recurrences of colorectal cancer , 1998, Diseases of the colon and rectum.

[14]  N. Petrelli,et al.  Clinical utility of external immunoscintigraphy with the IMMU-4 technetium-99m Fab' antibody fragment in patients undergoing surgery for carcinoma of the colon and rectum: results of a pivotal, phase III trial. The Immunomedics Study Group. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  N. Aaronson,et al.  Quality of life in colorectal cancer , 1995, Diseases of the colon and rectum.

[16]  L. Carey,et al.  CEA‐Directed Second‐look Surgery in the Asymptomatic Patient after Primary Resection of Colorectal Carcinoma , 1985, Annals of surgery.